Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Biocytogen Pharmaceuticals (Beijing) Co's Days Inventory for the
six
months ended in Jun. 2026 was 184.45.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Biocytogen Pharmaceuticals (Beijing) Co's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.99.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocytogen Pharmaceuticals (Beijing) Co's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.21.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Biocytogen Pharmaceuticals (Beijing) Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocytogen Pharmaceuticals (Beijing) Co's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Biocytogen Pharmaceuticals (Beijing) Co Total Inventories Related Terms
Biocytogen Pharmaceuticals (Beijing) Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Total Inventories Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Biocytogen Pharmaceuticals (Beijing) Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a Total Inventories of ¥219 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biocytogen Pharmaceuticals (Beijing) Co and its competitors.
Is Biocytogen Pharmaceuticals (Beijing) Co's Total Inventories too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Total Inventories is ¥219 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Total Inventories compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Total Inventories of ¥219 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Total Inventories is ¥219 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥76.48, compared to a current price of ¥134.13 — trading 75.4% above its estimated fair value. The current Total Inventories is ¥219 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current Total Inventories is ¥219 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of ¥134.13 is trading 75.4% above its estimated GF Value™ of ¥76.48.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for SHSE:688796:
Total Inventories: ¥219 Mil
GF Value™: ¥76.48 vs. price of ¥134.13 (75.4% above fair value)
No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a China-based biotechnology company that operates two main businesses: biopharmaceutical research and development, and preclinical research services. Its drug pipeline includes antibody therapeutics developed through its proprietary RenMab and related genetically engineered mouse platforms, which produce fully human antibodies for targets such as CD40, CTLA-4, and others in immuno-oncology. The company also provides preclinical models, gene-editing services, and antibody discovery services to pharmaceutical and biotechnology customers worldwide, generating revenue through research service fees, licensing arrangements, and collaboration agreements. Its animal model business supplies genetically modified mice and related products to academic and industry researchers. Biocytogen is headquartered in Beijing, China, and has expanded internationally, including operations in the United States and Europe, serving global pharmaceutical partners across oncology and other therapeutic areas.
53GF Score
Get the complete analysis for SHSE:688796
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688796 has been successfully added to your 
